The present invention relates to a method of producing a flavor by a co-fermentation process using mixed fermentation of two or more different microorganisms producing different products. The method of producing a flavor may produce a natural flavor capable of improving the taste and aroma of food and the overall sensory properties of food through a fermentation broth containing amino acids, nucleic acids and/or organic acids, which is produced by mixed fermentation of different microorganisms producing different products, that is, different kinds of amino acids, nucleic acids and/or organic acids. This flavor may be used in various food fields.

A gene ansB knockout mutant of Citrobacter werkmanii and an application thereof are provided. The gene ansB knockout mutant of the C. werkmanii is C. werkmanii with a gene ansB knocked out and a nucleotide sequence of the gene ansB is as shown in SEQ ID NO: 1. In the present invention, the acquired engineering bacteria with the gene ansB of the C. werkmanii knocked out are cultured in LB, TSB, NB and other media at 25° C. and 30° C., so that a biofilm formation capacity of the C. werkmanii on a polypropylene material is improved. Thus, the application scenarios and scopes of the C. werkmanii in heavy metal ion adsorption and construction of cellular protein synthesis micro-factories are broadened.

Lactobacillus sakei is provided, wherein the Lactobacillus sakei is Lactobacillus sakei TCI147 with an accession number of DSM 33913. A method for spermidine production with Lactobacillus sakei or metabolites thereof is provided, wherein the Lactobacillus sakei is Lactobacillus sakei TCI147 with an accession number of DSM 33913.

The present disclosure relates to a variant of cAMP receptor protein of Escherichia coli with alanine at position 35, a microorganism including the same, and a method of producing an L-amino acid using the same.

Bifidobacterium longum strains and cell wall fractions isolated from Bifidobacterium longum strains are useful in the prophylaxis or treatment of a respiratory viral infection in a subject. They are also useful in the prophylaxis of a secondary bacterial infection associated with a respiratory viral infection in a subject, especially a subject who is susceptible to respiratory infections.

Described is a method for the incorporation of formaldehyde into biomass comprising the following enzymatically catalyzed steps (1) condensation of pyruvate with formaldehyde into 4-hydroxy-2-oxobutanoic acid (HOB); (2) amination of the thus produced 4-hydroxy-2-oxobutanoic acid (HOB) to produce homoserine; (3) conversion of thus produced homoserine to threonine; (4) conversion of the thus produced threonine into glycine and acetaldehyde or acetyl-CoA; (5) condensation of the thus produced glycine with formaldehyde to produce serine; and (6) conversion of the thus produced serine to produce pyruvate, wherein said pyruvate can then be used as a substrate in step (1).

The invention relates to a process for culturing microbial cells producing a product of interest comprising fed-batch pre-culture.

The present disclosure discloses Stenotrophomonas pavanii capable of degrading polyethylene terephthalate, belonging to the technical field of microorganisms. The present disclosure provides a S. pavanii strain JWG-G1 capable of degrading polyethylene terephthalate (PET). After a seed solution of the S. pavanii is inoculated into an inorganic salt liquid medium containing 2 g/L polyethylene terephthalate at an inoculum size of 10% (v/v) and cultured for 5 d, polyethylene terephthalate (PET) particles can be partially degraded into monohydroxyethyl terephthalate and terephthalic acid that can be directly recycled. In addition, ester bond functional groups on the surface of the polyethylene terephthalate plastic particles can be reduced, and a weight loss rate of the polyethylene terephthalate plastic particles can reach 9.4%. Therefore, the S. pavanii JWG-G1 of the present disclosure has very high application prospects in the degradation of polyethylene terephthalate.

Provided herein are methods of treating graft-versus-host disease in a subject by administering pharmaceutical compositions containing bacterial strains of the Clostridia class. Also described herein are exemplary human-derived bacteria belonging to the Clostridia class, combinations of which have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions, and are therefore useful for mitigating pathological immune responses. Pharmaceutical compositions containing these and/or related bacteria can be used to prevent and treat immune-mediated diseases such as graft-versus-host disease.

The present disclosure provides novel bacterial strains with altered expression or start codon modification of one or more RNA degradation/processing genes. The RNA degradation genes of the present disclosure are controlled by heterologous promoters. The present disclosure further describes methods for generating microbial strains comprising heterologous promoter sequences operably linked to RNA degradation/processing genes.